EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Difluorinated thromboxane A 2 reveals crosstalk between platelet activatory and inhibitory pathways by targeting both the TP and IP receptors

Megan F Allen iD, James L Hutchinson iD, Michael Keith iD, Shahida Mallah iD, Robin A Corey iD, Justin S Trory iD, Changcheng Jing iD, Huaquan Fang iD, Liang Wei iD, Steven H Bennett iD, Varinder K Aggarwal iD, Stuart J Mundell iD und 1 weitere

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16435 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Megan F Allen und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Thromboxane A2, Receptors, Thromboxane. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Pharmacological Society, A.J. Clark PhD studentship M.K., National Centre for Replacement, Refinement and Reduction of Animals in Research, PhD studentship J.S.T., Engineering and Physical Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Thromboxane A 2 (TXA 2 ) is a prostanoid produced during platelet activaton, important in enhancing platelet reactivity by activation of TP receptors. However, due to the short half‐life, studying TXA 2 signalling is challenging. To enhance our understanding of TP receptor‐mediated platelet biology, we therefore synthesised mono and difluorinated TXA 2 analogues and explored their pharmacology on heterologous and endogenously expressed TP receptor function. Experimental Approach Platelet functional and signalling responses were studied using aggregometry, Ca 2+ mobilisation experiments and immunoblotting and compared with an analogue of the TXA 2 precursor prostaglandin H 2 , U46619. Gα q /Gα s receptor signalling was determined using a bioluminescence resonance energy transfer (BRET) assay in a cell line overexpression system. Key Results BRET studies revealed that F‐TXA 2 and F 2 ‐TXA 2 promoted receptor‐stimulated TP receptor G‐protein activation similarly to U46619. Unexpectedly, F 2 ‐TXA 2 caused reversible aggregation in platelets, whereas F‐TXA 2 and U46619 induced sustained aggregation. Blocking the IP receptor switched F 2 ‐TXA 2 ‐mediated reversible aggregation into sustained aggregation. Further BRET studies confirmed F 2 ‐TXA 2 ‐mediated IP receptor activation. F 2 ‐TXA 2 rapidly and potently stimulated platelet TP receptor‐mediated protein kinase C/P‐pleckstrin, whereas IP‐mediated protein kinase A/P‐vasodilator‐stimulated phosphoprotein was more delayed. Conclusion and Implications F‐TXA 2 is a close analogue to TXA 2 used as a selective tool for TP receptor platelet activation. In contrast, F 2 ‐TXA 2 acts on both TP and IP receptors differently over time, resulting in an initial wave of TP receptor‐mediated platelet aggregation followed by IP receptor‐induced reversibility of aggregation. This study reveals the potential difference in the temporal aspects of stimulatory and inhibitory pathways involved in platelet activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thromboxane A2Receptors, ThromboxaneHumansBlood PlateletsPlatelet ActivationSignal TransductionPlatelet AggregationInositol 1,4,5-Trisphosphate ReceptorsHEK293 Cells15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidReceptor Cross-Talk

Stichwörter der Autor:innen

BRETF2‐TXA2F‐TXA2G‐protein coupled receptorIP receptorTP receptorTXA2plateletsprostanoidsthromboxane A2

Substanzen

Thromboxane A2Receptors, ThromboxaneInositol 1,4,5-Trisphosphate Receptors15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid

Autor:innen und Institutionen

  • School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.
  • School of Chemistry, University of Bristol, Bristol, UK.

ORCID-Profile: Megan F Allen, James L Hutchinson, Michael Keith, Shahida Mallah, Robin A Corey, Justin S Trory, Changcheng Jing, Huaquan Fang, Liang Wei, Steven H Bennett, Varinder K Aggarwal, Stuart J Mundell, Ingeborg Hers

Förderung

  • British Pharmacological Society, A.J. Clark PhD studentship M.K.
  • National Centre for Replacement, Refinement and Reduction of Animals in Research, PhD studentship J.S.T.
  • Engineering and Physical Sciences Research Council
  • British Heart Foundation

Zitieren

APA

Allen, M. F., Hutchinson, J. L., Keith, M., Mallah, S., Corey, R. A., Trory, J. S., Jing, C., Fang, H., Wei, L., Bennett, S. H., Aggarwal, V. K., Mundell, S. J., & Hers, I. (2024). Difluorinated thromboxane A 2 reveals crosstalk between platelet activatory and inhibitory pathways by targeting both the TP and IP receptors. British Journal of Pharmacology. https://doi.org/10.1111/bph.16435

Vancouver

Allen MF, Hutchinson JL, Keith M, Mallah S, Corey RA, Trory JS, et al. Difluorinated thromboxane A 2 reveals crosstalk between platelet activatory and inhibitory pathways by targeting both the TP and IP receptors. British Journal of Pharmacology. 2024. doi:10.1111/bph.16435

BibTeX
@article{Allen2024,
  author = {Allen, Megan F and Hutchinson, James L and Keith, Michael and Mallah, Shahida and Corey, Robin A and Trory, Justin S and Jing, Changcheng and Fang, Huaquan and Wei, Liang and Bennett, Steven H and Aggarwal, Varinder K and Mundell, Stuart J and Hers, Ingeborg},
  title = {Difluorinated thromboxane A 2 reveals crosstalk between platelet activatory and inhibitory pathways by targeting both the TP and IP receptors},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16435}
}
Kostenlos starten →